In this context, some experiences have shown that a comprehensive treatment approach of surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) could be able to improve the prognosis of AEOC as reported in few clinical studies. Despite the established rationale and these encouraging results, a certain degree of skepticism still surrounds HIPEC in AEOC, involving inherent potential morbidity and the paucity of randomized data confirming its theoretical advantage. Moreover, the literature on HIPEC safety and efficacy in combination with bevacizumab is very less and therefore needs to be better investigated. Based on these considerations, we conducted a phase II monocentric, open label, non-randomized and single-arm study aimed to explore the feasibility of PDS and HIPEC upfront followed by first-line therapy with bevacizumab, as GOG-0218 schedule